Elizabeth G Gibson

Dr. Elizabeth G Gibson

Bristol-Myers Squibb (United States), New York, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2019 in ACS Infectious Diseases
Verified
Journal Article
Closed access
EGElizabeth G Gibson
Elizabeth G Gibson
BBBen Bax
Ben Bax
PCPan F. Chan
Pan F. Chan
Neil OsheroffNeil Osheroff
Neil Osheroff

5 March 2024 in ACS Infectious Diseases
Verified
Journal Article
Open access
AOAlexandria A. Oviatt
Alexandria A. Oviatt
EGElizabeth G Gibson
Elizabeth G Gibson
JHJianzhong Huang
Jianzhong Huang
KMKaren Mattern
Karen Mattern
KNKeir C. Neuman
Keir C. Neuman
Neil OsheroffNeil Osheroff
Neil Osheroff
Antimicrobial resistance is a global threat to human health. Therefore, efforts have been made to develop new antibacterial agents that address this critical medical issue. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial in clinical development. Recently, phase III clinical trials for gepotidacin treatment of uncomplicated urinary tract infections caused by uropathogens, including Escherichia coli, were stopped for demonstrated efficacy. Because of the clinical promise of gepotidacin, it is important to understand how the compound interacts with its cellular targets, gyrase and topoisomerase IV, from E. coli. Consequently, we determined how gyrase and topoisomerase IV mutations in amino acid residues that are involved in gepotidacin interactions affect the susceptibility of E. coli cells to the compound and characterized the effects of gepotidacin on the activities of purified wild-type and mutant gyrase and topoisomerase IV. Gepotidacin displayed well-balanced dual-targeting of gyrase and topoisomerase IV in E. coli cells, which was reflected in a similar inhibition of the catalytic activities of these enzymes by the compound. Gepotidacin induced gyrase/topoisomerase IV-mediated single-stranded, but not double-stranded, DNA breaks. Mutations in GyrA and ParC amino acid residues that interact with gepotidacin altered the activity of the compound against the enzymes and, when present in both gyrase and topoisomerase IV, reduced the antibacterial activity of gepotidacin against this mutant strain. Our studies provide insights regarding the well-balanced dual-targeting of gyrase and topoisomerase IV by gepotidacin in E. coli.

10 May 2018 in ACS Infectious Diseases
Verified
Journal Article
Closed access
EGElizabeth G Gibson
Elizabeth G Gibson
TBTim R Blower
Tim R Blower
MCMonica Cacho
Monica Cacho
BBBen Bax
Ben Bax
JBJames M. Berger
James M. Berger
Neil OsheroffNeil Osheroff
Neil Osheroff

31 August 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
EGElizabeth G Gibson
Elizabeth G Gibson
MKMcKenzie M. King
McKenzie M. King
SMSusan L. Mercer
Susan L. Mercer
Joseph DeweeseJoseph Deweese
Joseph Deweese

28 January 2020
Verified
Book Chapter
Closed access
PDF file
EGElizabeth G Gibson
Elizabeth G Gibson
AOAlexandria A. Oviatt
Alexandria A. Oviatt
Neil OsheroffNeil Osheroff
Neil Osheroff

17 July 2013 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
DJDavid A. Jacob
David A. Jacob
EGElizabeth G Gibson
Elizabeth G Gibson
SMSusan L. Mercer
Susan L. Mercer
Joseph DeweeseJoseph Deweese
Joseph Deweese